**Name of journal: World Journal of Anesthesiology**

**ESPS Manuscript NO: 6966**

**Columns: Review**

**Opioid misuse in Canada and critical appraisal of aberrant behavior screening tools**

Frankel GEC *et al*. Opioid misuse in Canada

Grace EC Frankel, Howard Intrater, Malcolm Doupe, Michael Namaka

**Grace EC Frankel, Howard Intrater, Malcolm Doupe, Michael Namaka,** Faculty of Pharmacy, University of Manitoba, Manitoba, R3E 0T5, Canada

**Author contributions:** Frankel GEC, Intrater H, Doupe M and Namaka M solely contributed to this paper.

**Correspondence to: Michael Namaka, PhD, Associate Professor,** Faculty of Pharmacy, University of Manitoba, Room 319, Apotex Centre, 750 McDermot Ave. Winnipeg, Manitoba, R3E 0T5, Canada. mike.namaka@umanitoba.ca

**Telephone:** +1-204-4748380 **Fax:** +1-204-4747617

**Received:** October 30, 2013 **Revised:** January 15, 2014

**Accepted: February 16, 2014**

**Published online:**

**Abstract**

The incidence of prescription opioid misuse in Canada is increasing. Initiatives for safe prescribing practices for opioid medications include risk assessment for current and future opioid misuse. A clinical screening tool that can be universally applied to all patient populations is currently not available. Our objective was to provide a brief narrative review on opioid misuse from a Canadian perspective as well as a critical appraisal of the available clinical screening tools for detecting aberrant behaviors associated with opioid misuse. The Drug Abuse Screening Test (DAST), Addiction Behaviors Checklist (ABC), Diagnosis, Intractability, Risk and Efficacy Inventory (DIRE), Pain Assessment and Documentation Tool (PADT), Prescription Drug Use Questionnaire (PDUQ), Prescription Opioid therapy Questionnaire (POTQ), Screener and Opioid Assessment for Patients with Pain (SOAPP), Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R), Pain Medication Questionnaire (PMQ), Opioid Risk Tool (ORT) and Current Opioid Misuse Measure were included in the following review. Overall, a wide variability in quality, sensitivity and specificity was observed between screening tools. There is an overall lack of applicability to diverse patient populations as the majority of screening tools have been validated in pain clinic populations only. To conclude, there is a great need for a validated and convenient aberrant behaviors risk assessment tool that can be applied to a diverse patient population in a clinical setting.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Opioid analgesics; Opioid-related disorders; Prescription drug misuse; Risk assessment; Drug-seeking behavior; Canada

**Core tip:** With the increase in opioid prescribing in Canada, prescription opioid misuse is a growing concern from a health care, financial and safety standpoint. Definitions regarding opioid misuse and covariate risk factors predictive of opioid misuse are controversial. The currently available risk assessment tools used to predict or detect opioid misuse vary in terms of sensitivity, specificity, quality, reproducibility and have been validated in very limited patient populations. There is a clear need for the development of a generalizable risk assessment tool to assess for prescription opioid misuse.

Frankel GEC, Intrater H, Doupe M, Namaka M. Opioid misuse in Canada and critical appraisal of aberrant behavior screening tools

**Available from:**

**DOI:**

**INTRODUCTION**

The prevalence of prescription drug abuse in Canada is on the rise, with opioids leading as the most abused class of medications. Next to the United States, Canada has the second-highest level of prescription opioid use globally. Over a 10 year period (2000-2010), the total number of opioid medications consumed in Canada rose by greater than 200%[[1](#_ENREF_1)]. Of this increase in opioid consumption, an analysis by Fischer and colleagues determined a higher prescribing prevalence of “strong opioids” such as oxycodone, hydromorphone, fentanyl, meperidine, methadone and morphine, whereas weak opioids such as codeine were prescribed less frequently over the 2005-2010 period[[2](#_ENREF_2)].

With increased opioid prescribing, misuse leading to addiction, overdose and death is a growing health issue. A population-based study in Ontario over a two-year period (2006-2008) showed 58% of drug-related deaths were attributed to opioid toxicity with oxycodone accounting for one-third of opioid-related deaths[[3](#_ENREF_3)]. From this same study, 7% of those who died used opioids prescribed for friends/family, 19% manipulated the dosage form (injections, inhalation, chewing), and 5% had been switched from another opioid near the time of death. Other behaviors such as diversion of opioids from heath care facilities (0.6%), intentional double doctoring (2.1%) and purchasing opioids from street sources (2%) existed. From a national perspective, the 2009 Canadian Alcohol and Drug Use Monitoring Survey (CADUMS) showed a prevalence of nonmedical prescription opioid analgesic use of 4.8% and 0.4% for those trying to “get high.”[[4](#_ENREF_4)] Finally, a meta-analysis estimated that 3.3% of chronic non-cancer pain patients taking opioid medications were addicted and 11.5% displayed aberrant behaviors[[5](#_ENREF_5)].

Currently, there exists an initiative towards the promotion of safe prescribing practices in Canada, particularly concerning the prescribing and monitoring of opioid medications. In March 2013 a report published by the Canadian Centre on Substance Abuse[[6](#_ENREF_6)] acknowledged the increase in non-medical use of prescription drugs as well as the increase in criminal activity surrounding diversion. This document outlines strategies such as provincial monitoring programs, stricter legal implications for possession/diversion of prescription medications as well as risk-reducing strategies such as controlling/restricting prescribing practices. Several provinces have already implemented provincial drug monitoring programs in the form of provincial databases as a tool to assist healthcare professionals in identifying/discouraging double-doctoring, refuse early fills, avoid harmful drug interactions/overdose and identify patients who misuse prescription opioids[[7](#_ENREF_7)].

An intuitive strategy to promote safe prescribing practices for opioid medications would entail the identification of patients at highest risk for misuse coupled with appropriate intervention. Risk stratification would directly influence pain treatment considerations as well as intensity of patient monitoring required if considering initiation of opioid therapy. Several screening tools to identify aberrant behaviors have been proposed in the literature. However, the validity and generalizability of these tools are often questionable due to several factors, as will be discussed. It has been demonstrated that no one risk factor can predict drug abuse in a given individual, but particular combinations of risk factors are more predictive than others[[8](#_ENREF_8)]. There is a clear need for the development and validation of a robust clinical risk assessment tool that both identifies aberrant behaviors and weights them appropriately. There are very few well-designed clinical trials of adequate duration, ideally long-term studies, which fulfil these requirements[[9](#_ENREF_9)].

The purpose of the following article is to provide a brief background on definitions and methods of opioid misuse, review covariate risk factors associated with opioid misuse as well as explore the available risk assessment tools for aberrant behaviors in terms of their practicality and generalizability to various practice settings.

**Definitions, methods and consequences of opioid misuse**

Prescription opioid misuse is considered a form of substance abuse. Table 1 provides an overview of definitions to differentiate clinical aspects of substance abuse[[8](#_ENREF_8),[10-13](#_ENREF_10)]. The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V)[[14](#_ENREF_14), [15](#_ENREF_15)] has revised its criteria for substance abuse by merging “substance abuse” and “substance dependence” into one category entitled “substance use disorder”. The severity of the disorder is rated on a continuum from mild to severe depending on the number of symptoms present (see Table 1 for details). One of the main reasons for the revision was the diagnosis of drug dependence was often confused with addiction. Patients on long-term opioid medications are considered physically dependent and/or tolerant but may not be addicted to the medication. It has been argued that these two criteria should not be used when assessing for a substance use disorder in patients on opioids, but this practice has not been validated by clinical studies[[8](#_ENREF_8)].

The 2009 Canadian Alcohol and Drug Use Monitoring Survey (CADMUS) estimated that approximately 19% of Canadians are using prescription opioid medications and 4.8% are using for non-medicinal purposes. In other words, approximately 1 in 20 patients prescribed opioid medications are not using them as prescribed[[4](#_ENREF_4)]. As this was a self-reported telephone survey, the prevalence of opioid misuse might be underreported. Some examples of opioid misuse include altering the dosage form (crushing, biting/chewing tablets, opening capsules, chewing fentanyl patches, crushing and injecting, cold water extractions/purifications of combination products), obtaining opioids in another manner (stealing/borrowing from friends/family members, purchasing off the street/internet, using another person’s identity to obtain a prescription, obtaining black market opioid sample cards, “double doctoring”), taking more opioid than prescribed or taking opioid medications in conjunction with alcohol or other sedating medications[[6](#_ENREF_6), [8](#_ENREF_8)].

Opioid misuse has several serious consequences (Table 2). First and most concerning, is mortality related to impaired functioning/motor-vehicle collisions, accidental overdoses and suicide. From 2006-2008, 58% of 2330 drug-related deaths in Ontario were related to opioid use[[3](#_ENREF_3)]. The addition of long-acting oxycodone to the Ontario drug formulary was associated with a 5-fold increase in oxycodone-related morality and a 41% increase in overall opioid-related mortality from 1991-2007[[16](#_ENREF_16)]. Second, burden of disease and overall harm of opioid medication misuse exceeds illicit drug use and is second to tobacco and alcohol[[1](#_ENREF_1)]. In 1999, projected health and social costs for each person addicted to opioids approximated $44000/year[[17](#_ENREF_17)]. In 2002, a survey regarding the costs of substance abuse in Canada reported opiates as the second leading contributor to hospital admissions/hospital days and admission for psychiatric reasons[[18](#_ENREF_18)]. Unfortunately, the report did not specifically address the proportion of admissions due to prescription opioids. A study on emergency room visits demonstrated a 250% increase in number of visits related to narcotic withdrawal, overdose, intoxication, psychosis and harmful use between 2005-2011[[17](#_ENREF_17)]. In addition, the number of detoxification admissions related to controlled-release oxycodone to the Centre of Addiction and Mental Health (CAMH) in Toronto demonstrated an increase from 3.8% to 55.4% over a 5-year period[[19](#_ENREF_19)]. Information on job status/productivity losses related to opioid misuse is currently unavailable from a Canadian perspective. Overall, there is a trend towards increased hospitalizations and increased enrollment into detoxification programs demonstrating an increase in health-care associated costs[[17](#_ENREF_17)]. Third, physicians have expressed concerns about prescribing opioid medications due to increased liability risks as well as increased potential for patient harm. It has been shown that family physicians prescribing opioid medications more frequently to their patients have resulted in increased contributions to opioid-related mortality. In one study, physicians in the uppermost quintile who prescribed opioids most frequently wrote the final prescription for 62.7% of patients whose death was related to opioids[[20](#_ENREF_20)]. Family physicians have voiced their concerns regarding the misuse/addiction potential of opioids, lack of specialized pain management knowledge as well as awareness of increasing government restrictions and investigations into opioid prescribing practices[[21](#_ENREF_21)]. Referral programs to specialized pain clinics have either long wait times (median of 6 mo for most pain clinics, 12 times longer than private multidisciplinary pain treatment facilities) or limited access with no specialist care available (*i.e.*, Prince Edward Island and the Territories)[[22](#_ENREF_22)]. As a result, over 95% of general practitioners have an active role in prescribing pain medications for their patients[[1](#_ENREF_1),[21](#_ENREF_21)]. Finally, the legal aspects of opioid misuse including diversion, robbery/theft and associated consequences such as increased crime rates and increased incarceration are a concerning aspect of opioid misuse. Data from Health Canada indicated that thefts/drug diversion from licenced dealers and Canadian pharmacies are a progressing issue. Oxycodone is of particular concern, with 340328 doses missing in 2010 from pharmacies, 168420 doses lost from licenced dealers, and over 300000 doses lost due to armed robbery or break-and-entry, representing a substantial increase since 2005[[1](#_ENREF_1)].

**Risk factors for opioid misuse**

A comprehensive review of the literature on identification of covariate risk factors for opioid misuse has been established[[8](#_ENREF_8),[23-25](#_ENREF_23)]. A summary of risk factors can be found in Table 2. It has been suggested that solitary risk factors are poorly predictive of opioid misuse. Having a combination of one risk factor from each domain of (1) psychosocial issues, (2) drug-related factors and (3) genetic factors most strongly predicts future likelihood of substance use[[8](#_ENREF_8)]. Rice and colleagues conducted a retrospective study with a primary objective of identifying patient characteristics and behaviors associated with a diagnosis of opioid abuse (*n* = 6380) versus those not diagnosed with opioid abuse (*n* = 815536) [[26](#_ENREF_26)]. The authors identified several “key characteristics” [defined as an odds ratio (OR) of > 2] contributing to increased risk of opioid abuse which included; prior opioid prescriptions, a larger number of prior opioid prescriptions (1-5 prescriptions or 6 or more prescriptions), prior prescription of buprenorphine or methadone, past history of non-opioid drug abuse, comorbid mental illness, comorbid hepatitis and having a family history of opioid abuse. Other factors such as younger age (OR 1.11) and male gender (OR 1.35) also showed to increase risk, which is a consistent finding from other studies[[23](#_ENREF_23),[24](#_ENREF_24)]. Perhaps most concerning is the fact that adolescents are especially at risk of opioid misuse. An Ontario study conducted in 2010-2011 reported a non-medical prescription opioid use prevalence of nearly 1 in 5 (20%) secondary students (grades 9-12) compared with 5.9% in the adult population[[25](#_ENREF_25)]. Considering previous drug use is a very strong predictor of future substance use, a high prevalence of non-medical use of prescription opioids in young individuals will likely influence their drug use habits in their adult years.

The presence of comorbid psychiatric conditions is a strong predictor of opioid misuse. Coexisting depression and/or anxiety has been shown to increase risk[[8](#_ENREF_8),[27](#_ENREF_27)]. Chronic pain patients report a greater frequency of depression and anxiety than patients with other medical conditions. Some studies have reported a 50%-85% prevalence of concomitant psychiatric conditions in patients with chronic pain[[24](#_ENREF_24)]. One study demonstrated that patients with a high psychiatric morbidity defined as ≥ 2 positive responses on the Prescription Drug-Use Questionnaire (PDUQ) were associated with younger age, longer duration on opioids, higher Screener and Opioid Assessment for Pain Patients (SOAPP) and Current Medication Misuse Measure (COMM) scores, greater incidence of abnormal urine drug screens and higher scores on the drug misuse index (DMI), indicating an overall increased risk for opioid misuse[[27](#_ENREF_27)]. To prevent future opioid misuse, treatment of the underlying mood disorder should be addressed prior to the initiation of opioid therapy.

Other predictors of future opioid misuse include drug related factors such as the use of immediate release opioid formulations, high daily doses of opioids and self-reported craving of opioid medication[[8](#_ENREF_8)]. Use of immediate release opioid medications (verses sustained release formulations) may increase risk of misuse due to the quick release of medication and capability of inducing a “high.” This theory is controversial as one prospective, comparative study found no difference in misuse between methadone and immediate release hydromorphone in 200 pain clinic patients[[28](#_ENREF_28)]. Wasan *et al*[[29](#_ENREF_29)] found that patients who reported craving opioids on the Prescription Drug Use Questionnaire (PDUQ) were more likely to misuse their medication.

The overall purpose of risk factor identification is to stratify patients into “low” and “high” risk groups in order to formulate an individualistic follow-up plan. The categorization of the patient will determine the vigilance and intensity in which monitoring and follow-up should occur.

**Aberrant drug behaviors: predicting misuse and critical appraisal of available screening tools**

As defined in Table 1, aberrant behaviorsinclude “behaviours that may cause suspicion about addiction in opioid-treated pain patients *or* behaviors outside the boundaries of the agreed-on treatment plan which is established as early as possible in the doctor-patient relationship.” Table 4 contains a descriptive list of potential aberrant behaviors. The Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain suggest that behaviors such as altering the route of delivery and/or obtaining opioids from other sources are highly indicative of addictive behavior, more so than other behaviors[[9](#_ENREF_9)].

To identify behaviors associated with opioid misuse, several screening tools have been developed. Table 5 provides an overview of commonly used screening tools for aberrant behaviors. A universally accepted or ”gold standard” screening tool for detecting aberrant behaviors in primary care patients on long-term opioid therapy for non-cancer pain management currently does not exist for several reasons[[30](#_ENREF_30)]. Validation studies for predictive value and sensitivity/specificity of the questionnaires are limited. Sensitivity of the questionnaire evaluates the ability of the screening tool to identify patients who would later display aberrant behaviors whereas specificity measures the ability of the tool to identify patients who will not show aberrant behaviors. The development of aberrant behavior risk assessment tools stemmed from specialty clinics for pain management, where opioid prescribing is high. Validation studies often had very small sample sizes and/or were targeting very specific patient populations (*i.e.*, veterans). Banta-Green and colleagues investigated the applicability of the prescription drug use questionnaire (PDUQ) to a general medical population and found a very poor internal reliability compared with the index study involving pain centre patients (0.56 *vs* 0.81 respectively) [[31](#_ENREF_31)]. Therefore, the overall generalizability of the questionnaires to diverse patient populations is poor[[32](#_ENREF_32)]. Further, the limitations of written screening tools in patients who are not able to understand the assessment questions (*i.e.*, brain damage, illiterate, blindness, language barriers) create selection bias as these patients may not be evaluated correctly due to lack or response or incomplete understanding. One study reported that 15% of patients were unable to complete ≥ 1 of the risk assessment measures[[33](#_ENREF_33)]. The survey items and tested domains vary considerably from tool to tool. Some tools are specific to outpatient prescription opioid therapy whereas others are designed to screen for overall substance abuse risk. Standardization of screening tools is therefore not present. One of the largest criticisms of the validation studies for aberrant behavior risk assessment tools is the fact that baseline aberrant behaviors are often used to compare predictive validity. Aberrant behaviors documented at the index clinic visit are used as a baseline to compare future incidence of aberrant behaviors. Intuitively, patients with baseline aberrant behaviors are more likely to exhibit behaviors in the future, therefore biasing the predictive ability of the tool towards a more positive result (producing a false increase in predictive reliability). In an attempt to eliminate this criticism, the investigators of the SOAPP screening tool revised and retested their tool (SOAPP-R)[[34](#_ENREF_34)]. Finally, many of the validation studies for aberrant behaviors risk assessment tools did not incorporate pain monitoring tools such as the Brief Pain Inventory (BPI) to monitor the control of patients’ pain. Uncontrolled pain may be misinterpreted as drug-seeking behavior, therefore confounding the predictive ability of the screening tool.

A comparison of screening tools for aberrant behaviors has been conducted in an attempt to identify the most reliable tool. Moore and colleagues compared the predictive ability of a clinical interview, the Screener and Opioid Assessment for Patients with Pain (SOAPP), Opioid Risk Tool (ORT) and Diagnosis, Intractability, Risk and Efficacy Inventory (DIRE) screening tools in a group of 48 patients discharged from a pain management clinic to detect likelihood of aberrant behaviors[[35](#_ENREF_35)]. The authors found the sensitivity was highest for the clinical interview (0.77), followed by SOAPP (0.72), ORT (0.45) and DIRE (0.17). Combining the clinical interview with the SOAPP assessment tool increased sensitivity to 0.90. In another study, Jones et al compared the Opioid Risk Tool (ORT), Pain Medication Questionnaire (PMQ), the Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R) and a detailed psychologist interview for sensitivity and specificity in chronic pain patients followed for 6 mo[[33](#_ENREF_33)]. The clinical psychologist had highest sensitivity, identifying 71% of the discharged patients for aberrant behavior. The 3 written measures had lower sensitivities; SOAPP-R (39%), PMQ (34%) and ORT (20%). For specificity, the ORT was most successful (88%), followed by PMQ (77%), SOAPP-R (69%) and clinical psychologist (60%). In 2009, the American Pain Society and American Academy of Pain Medicine published a clinical practice guideline attempting to evaluate the ability of available screening tools to predict future aberrant behaviors[[36](#_ENREF_36)]. The authors gave a quality score (maximum of nine points) to each of the assessment tools with one point awarded for a “yes” answer for the following domains: (1) Evaluates population other than the one used to derive the instrument; (2) Consecutive series of patients or a random subset; (3) Describes severity of symptoms, opioid dose/duration and underlying conditions; (4) Adequate description of screening instrument; (5) Appropriate criteria included in screening instrument; (6) Adequate description of method for identifying aberrant drug-related behaviors; (7) Appropriate criteria used to identify aberrant drug-related behaviors; (8) Aberrant drug-related behaviors assessed in all enrollees; and (9) Blinded assessment of aberrant drug-related behaviors.

Quality scores for the screening tools included in the analysis can be found in Table 5. The SOAPP-R assessment tool scored highest (6/9) amongst the initial screening tools with a prospective study design. Although the POTQ scored highest amongst the retrospective or cross-sectional studies (7/9), the criteria used to evaluate the quality of the screening tool was unclear in comparison to the original study design and therefore may not reflect a true quality rating.

**Discussion and Conclusion**

The clinical/psychological interview remains the optimal strategy to identify opioid misuse, likely due to its in-depth nature. The SOAPP-R tool has decent overall quality, predictability of discontinuation of opioids due to aberrant drug behaviors as well as sensitivity and specificity. In addition, it has been cross-validated in over 600 patients and has been found to identify approximately 80%-90% of patients who will eventually misuse opioids[[24](#_ENREF_24)]. These are likely the tools of choice, especially for initial clinic visits when the decision to initiate or continue opioids is being considered. As stated above, combining risk assessment tools with a clinical interview strengthens predictive ability. However, both the limitations and intended patient population of each tool should be considered when choosing a risk assessment tool for a particular clinic. Overall, the available screening tools are preliminary at best.

Another major gap in clinical knowledge is the degree of impact these screening tools have on clinical outcomes[[36](#_ENREF_36)]. To date, there is a paucity of evidence to suggest that more frequent follow up and stricter prescribing practices diminish the incidence of opioid misuse for “high risk” patients on opioids.

An ideal opioid risk assessment tool to detect aberrant behaviors should be both sensitive and specific, maintain internal and external validity, have a robust population base (ideally for primary care or a general outpatient clinic setting) written in uncomplicated, patient-friendly language and be concise/efficient to administer. An ongoing clinical study at Health Sciences Centre Pain Clinic is currently investigating a new aberrant behaviors checklist in chronic pain patients. The purpose of this study is to prospectively follow 150 patients on prescription opioid medications and trial an aberrant behaviors checklist for predictive validity and to assign weights to certain behaviors indicating greater or lesser predictability for opioid misuse. The results of this study could potentially add new data on specific aberrant behaviors that are most predictive of opioid misuse, leading to the development of a tool that could be subsequently validated for primary care use.

In conclusion, prescription opioid misuse in Canada is a serious public health issue that is increasing in prevalence and contributing significantly to patient morbidity and mortality. Chronic pain management goals include risk-assessment strategies to strive for optimal pain management while minimizing risk of opioid misuse. Identification of risk factors associated with opioid misuse can be a challenge due to variability between available risk assessment tools. A universal screening tool identifying aberrant behaviors would be the ideal standard of practice, similar to other chronic disease states that employ standard screening recommendations. Additional long-term validation studies in diverse patient populations are needed to improve and expand the current knowledge base. In addition, assessment of clinical relevance and impact of interventions for opioid misuse on patient outcomes are required. Strategies to curb opioid misuse should be a top priority from a governmental, financial and public health standpoint.

**References**

1 **Fischer B**, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. *Pain Physician* 2012; **15**: ES191-ES203 [PMID: 22786457]

2 **Fischer B**, Jones W, Krahn M, Rehm J. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. *Pharmacoepidemiol Drug Saf* 2011; **20**: 1269-1277 [PMID: 21755568 DOI: 10.1002/pds.2190]

3 **Madadi P**, Hildebrandt D, Lauwers AE, Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. *PLoS One* 2013; **8**: e60600 [PMID: 23577131 DOI: 10.1371/journal.pone.0060600]

4 **Shield KD**, Jones W, Rehm J, Fischer B. Use and nonmedical use of prescription opioid analgesics in the general population of Canada and correlations with dispensing levels in 2009. *Pain Res Manag* 2013; **18**: 69-74 [PMID: 23662288]

5 **Fishbain DA**, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. *Pain Med* 2008; **9**: 444-459 [PMID: 18489635 DOI: 10.1111/j.1526-4637.2007.00370.x]

6 Ulan S, Davidson C, Perron M. First Do No Harm: Responding to Canada's Prescription Drug Crisis. 2013 Available from: http: //www.ccsa.ca/2013 CCSA Documents/Canada-Strategy-Prescription-Drug-Misuse-Report-en.pdf

7 **Richard G**, Ojala V, Ojala A, Bowles SK, Banh HL. Monitoring programs for drugs with potential for abuse or misuse in Canada. *Can Pharm J (Ott)* 2012; **145**: 168-171 [PMID: 23509545 DOI: 10.3821/145.4.cpj168]

8 **Sehgal N**, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. *Pain Physician* 2012; **15**: ES67-ES92 [PMID: 22786463]

9 (NOUGG), N.O.U.G.G. Canadian Guideline for safe and effective use of opioids for chronic non-cancer pain: Practice Toolkit. 2010. Available from: http: //nationalpaincentre.mcmaster.ca/opioid/

10 **Webster L**, St Marie B, McCarberg B, Passik SD, Panchal SJ, Voth E. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain. *J Opioid Manag* 2011; **7**: 235-245 [PMID: 21823554 DOI: 10.5055/jom.2011.0066]

11 **Lourenço LM**, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use? *Expert Opin Drug Deliv* 2013; **10**: 229-240 [PMID: 23252692 DOI: 10.1517/17425247.2013.751095]

12 **Potter JS**, Marino EN. How to avoid opioid misuse. *J Fam Pract* 2013; **62**: S2-S7 [PMID: 23520590]

13 **Højsted J**, Sjøgren P. Addiction to opioids in chronic pain patients: a literature review. *Eur J Pain* 2007; **11**: 490-518 [PMID: 17070082 DOI: 10.1016/j.ejpain.2006.08.004]

14 American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. Vol. fifth. 2013, Arlington, VA: American Psychiatric Publishing

15 Paris J. The Intelligent Clinician's Guide to DSM-5. 2013, New York, NY: Oxford University Press

16 **Dhalla IA**, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. *CMAJ* 2009; **181**: 891-896 [PMID: 19969578 DOI: 10.1503/cmaj.090784]

17 Expert Working Group on Narcotic Addiction The Way Forward: Stewdardship for Prescription Narcotics in Ontario October 2012. 1-42 Available from: http: //www.health.gov.on.ca/en/public/publications/mental/docs/way\_forward\_2012.pdf

18 Balinuas JBS, Fischer B, Gnam W, Patra J, Popova S, Sarnocinska-Hart A, Taylor B. The Costs of Substance Abuse in Canada 2002: Highlights 2006. Available from: http: //www.ccsa.ca/2006 CCSA Documents/ccsa-011332-2006.pdf

19 **Sproule B**, Brands B, Li S, Catz-Biro L. Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids. *Can Fam Physician* 2009; **55**: 68-9, 69.e1-5 [PMID: 19155373]

20 **Dhalla IA**, Mamdani MM, Gomes T, Juurlink DN. Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. *Can Fam Physician* 2011; **57**: e92-e96 [PMID: 21402956]

21 **Wenghofer EF**, Wilson L, Kahan M, Sheehan C, Srivastava A, Rubin A, Brathwaite J. Survey of Ontario primary care physicians' experiences with opioid prescribing. *Can Fam Physician* 2011; **57**: 324-332 [PMID: 21402971]

22 **Peng P**, Choiniere M, Dion D, Intrater H, Lefort S, Lynch M, Ong M, Rashiq S, Tkachuk G, Veillette Y. Challenges in accessing multidisciplinary pain treatment facilities in Canada. *Can J Anaesth* 2007; **54**: 977-984 [PMID: 18056206 DOI: 10.1007/bf03016631]

23 **Jamison RN**, Butler SF, Budman SH, Edwards RR, Wasan AD. Gender differences in risk factors for aberrant prescription opioid use. *J Pain* 2010; **11**: 312-320 [PMID: 19944648 DOI: 10.1016/j.jpain.2009.07.016]

24 **Jamison RN**, Edwards RR. Risk factor assessment for problematic use of opioids for chronic pain. *Clin Neuropsychol* 2013; **27**: 60-80 [PMID: 22935011 DOI: 10.1080/13854046.2012.715204]

25 **Fischer B**, Ialomiteanu A, Boak A, Adlaf E, Rehm J, Mann RE. Prevalence and key covariates of non-medical prescription opioid use among the general secondary student and adult populations in Ontario, Canada. *Drug Alcohol Rev* 2013; **32**: 276-287 [PMID: 23305232 DOI: 10.1111/dar.12025]

26 **Rice JB**, White AG, Birnbaum HG, Schiller M, Brown DA, Roland CL. A model to identify patients at risk for prescription opioid abuse, dependence, and misuse. *Pain Med* 2012; **13**: 1162-1173 [PMID: 22845054 DOI: 10.1111/j.1526-4637.2012.01450.x]

27 **Wasan AD**, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. *Clin J Pain* 2007; **23**: 307-315 [PMID: 17449991 DOI: 10.1097/AJP.0b013e3180330dc5]

28 **Manchikanti L**, Manchukonda R, Pampati V, Damron KS. Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short-acting (hydrocodone) or long-acting (methadone) opioids. *Pain Physician* 2005; **8**: 257-261 [PMID: 16850081]

29 **Wasan AD**, Butler SF, Budman SH, Fernandez K, Weiss RD, Greenfield SF, Jamison RN. Does report of craving opioid medication predict aberrant drug behavior among chronic pain patients? *Clin J Pain* 2009; **25**: 193-198 [PMID: 19333168 DOI: 10.1097/AJP.0b013e318193a6c4]

30 **Gianutsos LP**, Safranek S, Huber T. Clinical inquiries: is there a well-tested tool to detect drug-seeking behaviors in chronic pain patients? *J Fam Pract* 2008; **57**: 609-610 [PMID: 18786335]

31 **Banta-Green CJ**, Merrill JO, Doyle SR, Boudreau DM, Calsyn DA. Measurement of opioid problems among chronic pain patients in a general medical population. *Drug Alcohol Depend* 2009; **104**: 43-49 [PMID: 19473787 DOI: 10.1016/j.drugalcdep.2009.03.022]

32 **Kahan M**, Mailis-Gagnon A, Wilson L, Srivastava A. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population. *Can Fam Physician* 2011; **57**: 1257-166, 1257-166, [PMID: 22084455]

33 **Jones T**, Moore T, Levy JL, Daffron S, Browder JH, Allen L, Passik SD. A comparison of various risk screening methods in predicting discharge from opioid treatment. *Clin J Pain* 2012; **28**: 93-100 [PMID: 21750461 DOI: 10.1097/AJP.0b013e318225da9e]

34 **Butler SF**, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). *J Pain* 2008; **9**: 360-372 [PMID: 18203666 DOI: 10.1016/j.jpain.2007.11.014]

35 **Moore TM**, Jones T, Browder JH, Daffron S, Passik SD. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. *Pain Med* 2009; **10**: 1426-1433 [PMID: 20021601 DOI: 10.1111/j.1526-4637.2009.00743.x]

36 **Chou R**, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. *J Pain* 2009; **10**: 131-146 [PMID: 19187890 DOI: 10.1016/j.jpain.2008.10.009]

37 **Fishbain DA**, Cole B, Lewis JE, Gao J. Is smoking associated with alcohol-drug dependence in patients with pain and chronic pain patients? An evidence-based structured review. *Pain Med* 2012; **13**: 1212-1226 [PMID: 22845022 DOI: 10.1111/j.1526-4637.2012.01446.x]

38 **Passik SD**, Kirsh KL. Assessing aberrant drug-taking behaviors in the patient with chronic pain. *Curr Pain Headache Rep* 2004; **8**: 289-294 [PMID: 15228888]

39 **Yudko E**, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. *J Subst Abuse Treat* 2007; **32**: 189-198 [PMID: 17306727 DOI: 10.1016/j.jsat.2006.08.002]

40 **Webster LR**, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. *Pain Med* 2005; **6**: 432-442 [PMID: 16336480 DOI: 10.1111/j.1526-4637.2005.00072.x]

41 **Belgrade MJ**, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. *J Pain* 2006; **7**: 671-681 [PMID: 16942953 DOI: 10.1016/j.jpain.2006.03.001]

42 **Butler SF**, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. *Pain* 2004; **112**: 65-75 [PMID: 15494186 DOI: 10.1016/j.pain.2004.07.026]

43 **Akbik H**, Butler SF, Budman SH, Fernandez K, Katz NP, Jamison RN. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). *J Pain Symptom Manage* 2006; **32**: 287-293 [PMID: 16939853 DOI: 10.1016/j.jpainsymman.2006.03.010]

44 **Wu SM**, Compton P, Bolus R, Schieffer B, Pham Q, Baria A, Van Vort W, Davis F, Shekelle P, Naliboff BD. The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. *J Pain Symptom Manage* 2006; **32**: 342-351 [PMID: 17000351 DOI: 10.1016/j.jpainsymman.2006.05.010]

45 **Butler SF**, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N, Jamison RN. Development and validation of the Current Opioid Misuse Measure. *Pain* 2007; **130**: 144-156 [PMID: 17493754 DOI: 10.1016/j.pain.2007.01.014]

46 **Holmes CP**, Gatchel RJ, Adams LL, Stowell AW, Hatten A, Noe C, Lou L. An opioid screening instrument: long-term evaluation of the utility of the Pain Medication Questionnaire. *Pain Pract* 2006; **6**: 74-88 [PMID: 17309714 DOI: 10.1111/j.1533-2500.2006.00067.x]

47 **Adams LL**, Gatchel RJ, Robinson RC, Polatin P, Gajraj N, Deschner M, Noe C. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. *J Pain Symptom Manage* 2004; **27**: 440-459 [PMID: 15120773 DOI: 10.1016/j.jpainsymman.2003.10.009]

48 **Compton P**, Darakjian J, Miotto K. Screening for addiction in patients with chronic pain and "problematic" substance use: evaluation of a pilot assessment tool. *J Pain Symptom Manage* 1998; **16**: 355-363 [PMID: 9879160]

49 **Michna E**, Ross EL, Hynes WL, Nedeljkovic SS, Soumekh S, Janfaza D, Palombi D, Jamison RN. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. *J Pain Symptom Manage* 2004; **28**: 250-258 [PMID: 15336337 DOI: 10.1016/j.jpainsymman.2004.04.007]

50 **Passik SD**, Kirsh KL, Whitcomb L, Portenoy RK, Katz NP, Kleinman L, Dodd SL, Schein JR. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. *Clin Ther* 2004; **26**: 552-561 [PMID: 15189752]

**P-Reviewers:** Mégarbane B, Kvolik S, Wang X **S-Editor:** Song XX **L-Editor:** **E-Editor:**

**Table 1 Definitions[**[**8**](#_ENREF_8)**,**[**10-13**](#_ENREF_10)**]**

|  |  |
| --- | --- |
| **Tolerance** | A state of adaptation where fixed doses of opioids over time results in the need for increasing doses to maintain the same effect  |
| **Physical dependence**  | A state of adaptation manifested by a drug class-specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist |
| **Dependence****(DSM-V criteria)[**[**14**](#_ENREF_14)**]**  | A substance use disorder as a maladaptive pattern leading to clinically significant impairment or distress for at least 12 mo and meet ≥ 2 of the following:Recurring opioid use leading to a failure to fulfill role obligationsSocietal and interpersonal problemsUsing opioids in situations that are physically hazardousToleranceWithdrawalTaking opioid in larger amounts and for longer periods than intendedUnsuccessful at cutting down Spending time to obtain or use the opioidGiving up activities due to opioid useContinuing use despite physical or psychological problemsCraving or strong urge to use the opioid  |
| **Aberrant behavior** | Behaviours that may cause suspicion about addiction in opioid-treated pain patients ora behavior outside the boundaries of the agreed-on treatment plan which is established as early as possible in the doctor-patient relationship  |
| **Misuse** | Use of a medication for non-medical use or for reasons other than prescribed. Wilful or unintentional use of a substance in a manner not consistent with legal or medical guidelines such as altering dosage forms, sharing medications with the potential for harmful consequences.  |
| **Abuse**  | Misuse with consequences. The use of a substance to modify/control mood or state of mind (to obtain a “high”) in a manner that is illegal or harmful to oneself or others. Examples of potential consequences include accident, injuries, blackouts, legal issues, and sexual behavior increasing the risk of sexually-transmitted diseases.  |
| **Addiction** | A primary, chronic, neurobiological disease with genetic, psychosocial and environmental factors influencing its development and manifestations. It is characterized by compulsive use, continued use despite harm and craving.  |
| **Diversion**  | The unintentional transfer of a controlled substance from legitimate distribution and dispensing channels into illegal channels or obtaining a substance by an illegal method.  |

**Table 2 Consequences of Opioid Misuse[**[**1**](#_ENREF_1)**,**[**3**](#_ENREF_3)**,**[**8**](#_ENREF_8)**,**[**17**](#_ENREF_17)**,**[**18**](#_ENREF_18)**,**[**21**](#_ENREF_21)**]**

|  |
| --- |
| Overdose-related death  |
| Deteriorating social relationships  |
| Reduced productivity/increased disability |
| Increased morbidity (opioid related side-effects/withdrawal symptoms, hyperalgesia)  |
| Increased healthcare utilization/increased healthcare costs |
| Increased risk of blood-borne diseases (associated with injection drug use)  |
| Malpractice claims |
| Increased drug diversion |
| Legal repercussions  |

**Table 3 Risk factors associated with opioid misuse[**[**8**](#_ENREF_8)**,**[**23**](#_ENREF_23)**,**[**24**](#_ENREF_24)**,**[**26**](#_ENREF_26)**,**[**27**](#_ENREF_27)**,**[**37**](#_ENREF_37)**]**

|  |  |
| --- | --- |
| Non-modifiable risk factors | Age: Younger age (inverse risk relationship) Gender: Males (Caucasian) Women misuse due to emotional issues versus men who misuse due to legal/behavioral issuesGenetics:Family history of substance use disorder(s)Variations in μ-opioid receptor gene 1 (OPRM1)Pre-proenkephalin (PENK) gene polymorphisms  |
| Reported pain severity/type of pain | Multiple pain complaintsChronic back pain Report greater degree of pain-related limitations  |
| Comorbid psychological factors | History of substance use (cannabis, alcohol and other illicit drugs especially)Concomitant mood disorder, depression and/or anxiety Multiple psychosocial stressors Interpersonal problems with coworkers/family/friends History of risk-taking or thrill-seeking behaviorFrequent contact with high-risk individuals or environments  |
| Drug-related factors | Self-reported craving High daily doses (≥ 120 mg morphine equivalents per day)Use of short-acting opioids  |

**Table 4 Aberrant drug-behaviors[**[**5**](#_ENREF_5)**,**[**9**](#_ENREF_9)**,**[**38**](#_ENREF_38)**]**

|  |  |
| --- | --- |
| Indicator | Examples |
| Altering route of delivery1 | Injecting, biting, crushing, separating oral formulations |
| Accessing opioids from other sources1 | Obtaining the drug from friends/relativesSelling/purchasing from the “street”Double-doctoringAltering or creating fraudulent prescriptionsDrug hoarding/tradingMultiple emergency room visits  |
| Unsanctioned use | Unauthorized dose escalationsBinge use |
| Drug seeking behavior | Repeat prescription losses1Aggressive requesting of higher dosesHarassing staff for faxed prescriptions or “emergency” fit-in appointmentsManipulation of the prescribing physician Claiming nothing else “works”/ requesting specific opioid1 |
| Repeated withdrawal symptoms | Dysphoria, myalgias, GI symptoms, cravings, nausea/vomiting etc.  |
| Co-morbid conditions | Addicted to illicit drug, alcohol, cannabis and/or sedatives/hypnotics Underlying mood/anxiety disorders unresponsive to treatment |
| Social irregularity | Deteriorating/poor social functionConcern expressed by family members |
| Views on opioid medication  | Sometimes acknowledges being addictedStrong resistance to tapering or switching opioidsAdmits to mood-levelling effectsAcknowledges distressing withdrawal symptoms  |

1Associated with higher risk of addiction than others.

**Table 5 Overview of Aberrant drug-related behaviors risk assessment tools**

|  |
| --- |
| **Substance abuse assessment tools**  |
| Name of assessment tool and type of study  | **Description** | **Who administers and time to administer** | **Interpretation of results** | **Validated** | **Sensitivity/****specificity** | **Limitations**  | **Intended use**  | **Quality score[**[**36**](#_ENREF_36)**]** |
| Drug abuse screening test[[39](#_ENREF_39)]Prospective/ multiple studies | 28-item yes/no questionnaire to assess drug dependence or abuse (shorter versions of 10 or 20 items also available)  | Patient;5-10 min | A score of 6 or more indicates a drug abuse or dependence problem  | Yes | 0.81-0.96/ 0.71-0.94 | Test and retest were only a few weeks apart (psychometrics may be falsely better), susceptible to patient deception. Also hasn’t been extensively tested in pain patients, therefore not specific to opioid use  | For the initial assessment of drug abuse or dependence  | N/A  |
| **Risk assessment tools** |
| Opioid risk tool1[[40](#_ENREF_40)]Prospective | A 5-domain checklist (family history of substance abuse, personal history of substance abuse, age, history of sexual abuse and psychological disease) gender stratified and weighted | Patient;< 2 min | Low risk 0-3 pointsModerate risk 4-7 pointsHigh risk ≥ 8 points  | Yes  | *c* statistic for male model = 0.82 and female = 0.85 (both excellent discrimination) Sensitivity to detect discontinuance of opioids due to ADRB = 0.45 [[35](#_ENREF_35)]  | Has only been validated in a pain clinic, therefore applicability outside this population is limited | To be used as a risk assessment tool for aberrant behaviors prior to initial opioid prescription  | 4/9 |
| Diagnosis, intractability, risk and efficacy inventory[[41](#_ENREF_41)]Retrospective  | 7 item questionnaire - 4 domains (Diagnosis, Intractability, Risk and Efficacy) with the domain of Risk divided into 4 subcategories (psychological, chemical health, reliability and social support) to determine if a patient is suitable for maintenance opioid therapy  | Physician;< 2 min | Each questions is scored from 1 (least compelling/favorable) to 3 (most compelling/favorable). A score of ≤ 13 indicates an unsuitable candidate for maintenance opioid therapyA score of ≥ 14 indicates a good candidate with higher scores with a greater likelihood of successful prescription  | Yes  | Sensitivity to detect discontinuance of opioids due to ADRB = 0.17[[35](#_ENREF_35)]To predict patient compliance = 0.94/0.87 | Used primary care vignettes versus real-time patients, small sample size (N=61), drew upon patient cases in a referral centre (may not be generalizable), prospective validation needed  | A decision tool to assess reliability of patients prescribed high risk therapy (opioids) in a primary care setting.  | N/A |
| Screener and opioid assessment for patients with pain1[[36](#_ENREF_36),[42](#_ENREF_42),[43](#_ENREF_43)]Prospective | 14-item questionnaire with answers scored on a Likert 5-point scale of 0 (never) to 4 (very often) regarding drug history and other aberrant behaviors | Patient;< 5 min | A score of ≥ 8 indicates “high risk” of future aberrant drug related behaviors   | Yes  | Original Validation study 0.86/0.73 Sensitivity to detect likelihood of discontinuance of opioids due to ADRB = 0.72[[35](#_ENREF_35)] | Predictive validity questionable as self-reported aberrant behaviors at baseline were compared to those at follow-up; also used PDUQ to identify/include higher-risk pain clinic participants (N=175) | For the initial assessment of aberrant behaviors prior to initiating opioid therapy | 5/9 |
| Screener and opioid assessment for patients with pain– revised1[[34](#_ENREF_34)]Prospective  | 24-item questionnaire with answers scored on a Likert 5-point scale of 0 (never) to 4 (very often) regarding drug history and other aberrant behaviors  | Patient;2-5 min | Scores range from 0-96Low risk < 18 pointsHigh risk ≥ 18 points  | Yes  | Original validation study 0.81/0.68Ability to predict discharge from opioid treatment 0.39/0.69 [[33](#_ENREF_33)]Ability to predict presence of aberrant behaviors 0.41/0.71 [[33](#_ENREF_33)] | Has only been validated in a pain management clinic setting, less sensitive and specific than original SOAPP tool | For the initial assessment of aberrant behaviors prior to initiating opioid therapy  | 6/9 |
| **Ongoing assessment tools (Monitoring)**  |
| Addiction behaviors checklist 1[[44](#_ENREF_44)]Prospective cohort | 20-item yes/no questionnaire evaluating aberrant behaviors since last clinic visit and within current clinic visit  | Physician;5-10 min | A score of ≥ 3 “yes” answers indicates possible inappropriate opioid use and should alert physician to investigate further  | Yes | 0.88/0.86 | Validation study conducted in predominantly male veterans and some high risk patients were excluded | A tool to assess previous and current/ongoing aberrant behaviors of patients on opioids | 4/9 |
| Current opioid misuse measure1[[45](#_ENREF_45)]Cross-sectional | 17-item questionnaire with answers scored on a Likert scale from 0 (never) to 4 (very often) assessing the frequency of aberrant behaviors in the previous 30 days  | Patient;< 10 min | A cut-off score of ≥ 10 weakly increases the risk for ADRB | Yes  | 0.74/0.73 | Has only been validated in a pain management centre, small follow-up sample size (N=87), cross-validation studies are pending, limited evidence  | To be used as a monitoring tool for aberrant behaviors in chronic pain patients  | 5/9 |
| Pain medication questionnaire[[46](#_ENREF_46),[47](#_ENREF_47)]Cross-sectionalProspective cohort (long-term evaluation)  | 26-item self-assessment questionnaire with answers scored on a Likert 5-point scale of 0 (disagree) to 4 (agree)  | Patient;5-10 min | Low risk 0-34 pointsHigh Risk: 70-104 points High risk patients are associated with history of substance abuse, higher psychosocial distress and poorer functioning  | Yes | None available  | Has only been validated in a pain management clinic setting  | An assessment tool for ongoing aberrant behaviors  | 6/94/9 (long-term) |
| Prescription drug use questionnaire 1[[31](#_ENREF_31),[48](#_ENREF_48)]Cross-sectional   | 42-item yes/no questionnaire evaluating 6 domains: evaluation of pain condition, opioid use patterns, social/family factors, family history, history of substance abuse and psychiatric history.  | Physician;15 min | Each “yes” answer counts as one point. A score of 15 or greater indicates a substance use disorder | Yes, but poor results  | Cronbach’s coefficient for reliabilityα=0.81 in original study with pain clinic patients but decreased to α=0.56 in a general medical setting  | Evaluates risk at a single time point, very lengthy/time consuming. Pain clinic patients only; designed to be administered by a mental health care practitioner. Performed poorly in a general medical population  | A tool for addictive behaviors to be used in conjunction with other clinical criteria (DSM) to assess for the presence of addictive disease  | 6-7/9 |
| Prescription opioid therapy questionnaire 1[[49](#_ENREF_49)]Retrospective  | Substance Abuse History Interview (3 questions) plus checklist of 6 aberrant behaviors  | Physician;2-5 min | Each item checked on substance abuse history equals one point* 1. low risk

2-3 high risk  | Yes  | Sensitivity and specificity for each of the 6 aberrant behaviors determined [[36](#_ENREF_36)] but some inconsistencies with original study | Limited to a pain clinic population, developed using retrospective chart review  | A screening tool to identify substance abuse history and ongoing aberrant behaviors  | 7/92  |
| **Documentation tools**  |
| Patient assessment and documentation tool1[[50](#_ENREF_50)]Cross-sectional (field tested) | A 41-item clinician-directed interview chart note tool divided into 4 domains (4 A’s): analgesia, activities of daily living, adverse events and aberrant drug-related behaviors  | Physician;10-15 min | A descriptive tool to aid in documentation (chart note)  | Field-tested, but not validated  | N/A  | Descriptive tool; validation needed (no sensitivity or specificity data available) | A documentation tool to organize chart note information related to opioid use  | N/A |

1Recommended for use in the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain Practice Toolkit[[9](#_ENREF_9)]; 2Method of quality determination not consistent with original study design therefore questionable interpretation. ADRB: Aberrant drug-related behaviors; N: Sample size; N/A: Not assessed.